Please login to the form below
ixabepilone
This page shows the latest ixabepilone news and features for those working in and with pharma, biotech and healthcare.
Bayer fails to overturn Nexavar compulsory licence in India
There have already been suggestions that Roche's breast cancer treatment Herceptin (trastuzumab) and Bristol-Myers Squibb's leukaemia medicine Sprycel (dasatinib) and chemotherapy Ixempra (ixabepilone) could follow Nexavar down this
Latest news
-
India could hit Roche and BMS with compulsory licences
Sprycel (dasatinib) and its chemotherapy Ixempra (ixabepilone).
-
Triple negative breast cancer
One compound that works via this method is ixabepilone, which binds tubulin and promotes tubulin stabilisation whereby cell division cannot be completed. ... Bristol-Myers Squibb is also investigating ixabepilone in combination with cetuximab in the
-
Eisai wins approval for breast cancer drug
and with Bristol-Myers Squibb's Ixempra (ixabepilone), which is marketed for patients with late- stage disease after failure of an anthracycline, taxane and Xeloda.
-
Bristol-Myers signs cancer drug deal
BMS' existing cancer-drug portfolio includes Erbitux (cetuximab), Ixempra (ixabepilone) and Sprycel (dasatinib).
-
FDA approves BMS chemotherapy drug
The FDA has approved US-based pharmaceutical company Bristol-Myers Squibb's (BMS) new drug to treat advanced breast cancer, Ixempra (ixabepilone).
Triple negative breast cancer
More from news
Approximately 1 fully matching, plus 6 partially matching documents found.
Subscribe to our email news alerts
- Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults
- Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO
- FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies
- Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership
- New blood test to reduce heart attacks and death rates in A&E heart patients
- Clairvoyant commercialisation
No results were found
PMHub
Impetus Digital
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
